Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $143000.0.

  • Enanta Pharmaceuticals' Capital Expenditures fell 9836.48% to $143000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year decrease of 8342.47%. This contributed to the annual value of $12.9 million for FY2025, which is 2814.8% down from last year.
  • Enanta Pharmaceuticals' Capital Expenditures amounted to $143000.0 in Q4 2025, which was down 9836.48% from $1.5 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Capital Expenditures ranged from a high of $9.0 million in Q3 2024 and a low of $33000.0 during Q3 2021
  • Moreover, its 5-year median value for Capital Expenditures was $1.4 million (2022), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Capital Expenditures surged by 425454.55% in 2022, and later crashed by 9836.48% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Capital Expenditures stood at $363000.0 in 2021, then skyrocketed by 769.42% to $3.2 million in 2022, then tumbled by 75.06% to $787000.0 in 2023, then surged by 1011.18% to $8.7 million in 2024, then crashed by 98.36% to $143000.0 in 2025.
  • Its last three reported values are $143000.0 in Q4 2025, $1.5 million for Q3 2025, and $155000.0 during Q2 2025.